biotech · Fabry Disease · Bioequivalence · PLX
Protalix Biotherapeutics
Protalix BioTherapeutics
Protalix Biotherapeutics trial registry — 27 ClinicalTrials.gov studies with program phase, status, and indication context.
2 Snunit St., Science Park, POB 455, Carmiel, 2161401, IL, HACKENSACK, NJ, USA HQ
1994 Founded
197 Employees
Public company Type
PLX · NYSE Ticker
Company details
- Status
- Public
- HQ
- 2 Snunit St., Science Park, POB 455, Carmiel, 2161401, IL, HACKENSACK, NJ, USA
- Founded
- 1994
- Employees
- 197
- Programs
- 21
- Drugs
- 14
- Patents
- 22
Protalix Biotherapeutics clinical trials
Registry index of 27 ClinicalTrials.gov studies linked to Protalix Biotherapeutics programs — each row shows trial ID, program name, phase, status, and indication.
Protalix Biotherapeutics trial registry — 27 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for Protalix Biotherapeutics.
-
PL2200 Aspirin Capsules — Phase 3
Clinical update -
Pegunigalsidase alfa — Phase 3
Clinical update -
acetylsalicylic acid — Phase 2
Clinical update -
PRX-115 — Phase 2
Clinical update -
Human Glucocerebrosidase (prGCD) — Phase 1
Clinical update -
AIR DNase — Phase 1
Clinical update -
AIR DNase™ — Phase 2
Clinical update -
PRX-102 (pegunigalsidase alfa) — Phase 3
Clinical update